4sc Ag

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Bayer Pharma Aktiengesellschaft

4sc Discovery Gmbh

Volker Gekeler

Astrid Zimmermann

Thomas Maier

Thomas Beckers

Hemant Joshi

Matthias Vennemann

Thomas Bär

Swen Hölder

Armin Zülch

Sanjeev Anant Kulkarni

Ganesh S Chaure

Hans-Peter Hofmann

Anil P Jagtap

Sarvesh S Patel

Petra Gimmnich

Gerrit Beneke

Umesh Bhise

Sunil Chavan

Sachin Shivatare

Vikas Gore

Siegfried Schneider

Yogesh Munot

Beate Schmidt

Thomas Baer

Mathias Schmidt

Steffen Weinbrenner

Alexander Weber

Frank Dullweber

Thomas Stengel

Florian Dehmel

Uday Joshi

Jürgen Braunger

Mahindra Makhija

Dipak Harel

Thomas Bãr

Kamlesh Padiya

Juergen Braunger

Astrid Leja

Sanjeev A Kulkarni

Kamlesh J Padiya

Sarvesh A Patel

Yogesh S Munot

Sachin S Shivatare

Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.

Substituted imidazoquinolines

Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

Fused bicyclic imidazoles

Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors. 

N-sulphonylpyrroles and their use as histone deacetylase inhibitors

Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

Fused bicyclic pyrimidines

Compounds of a certain formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.

Indolopyridines as Eg5 kinesin modulators

The compounds of formula (I), wherein ring D and ring E together form a fused ring system selected from formula (II), (III), (IV), (V), (VI), (VII), and the salts of these compounds are novel, effective inhibitors of histone deacetylases. 

Tetrahydro-fused pyridines as histone deacetylase inhibitors

The invention relates to thiophene-imidazopyridine compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of PIk1. 

Thiophene-imidazopyridines

Compounds of a certain formula (I) in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Growing community of inventors

Constance, Germany

Volker Gekeler